Immunovant Shares Rise After Positive Clinical Trial Results for Arthritis Treatment
Immunovant (NASDAQ:IMVT) shares reached a five-year high following positive results from its clinical trial of IMVT-1402, showing strong response rates in treating rheumatoid arthritis. The company reported ACR20/50/70 scores at 72.7%, 54.5%, and 35.8% respectively by Week 16.
Tickers: $IMVT
Topics: biopharmaceutical rheumatoid_arthritis stock_movement